Search

This book discusses recent advances in the field of translational stroke research. The editors have designed the book to provide new insight into the importance of regeneration and repair mechanisms for stroke victims. The editors have brought together a talented group of international stroke researchers and clinicians to contribute to this volume, which is written for students, researchers and physicians in biotechnology, neurosciences, neurology, neuroradiology and neurosurgery.Throughout the world, stroke is still a leading cause of mortality and morbidity; there are 152,000 strokes in the United Kingdom, 62,000 in Canada, and approximately 15 million people worldwide. Large communities of stroke survivors are eagerly awaiting scientific advances in translational stroke research related to regeneration and recovery of function that would offer new therapeutics for rehabilitation and regeneration utilizing novel stem cell and molecular-based approaches. This volume will allow the reader to undersnd the future of stroke treatment from its inception in the laboratory through to clinical trial design. The reader will learn about the recent advances made in these areas related to basic and applied stroke research and their translational potential.Dr. Paul A. Lapchak is Professor of Neurology and Director of Translational Research in the Departments of Neurology & Neurosurgery at Cedars-Sinai Medical Center in Los Angeles CA, USA. Dr. Lapchak is an internationally recognized expert conducting translational drug development research for ischemic and hemorrhagic stroke. Dr. John H. Zhang is Professor of Anesthesiology, Neurosurgery, Neurology, and Physiology, and Director, Center for Neuroscience Research at Loma Linda University School of Medicine, Loma Linda, CA, USA. Dr. Zhang is an internationally recognized expert working on drug development for hemorrhagic stroke.

This book mainly discusses the current status of stroke transnational research and allows the reader to understand the interplay of common comorbidities in the stroke population such as diabetes and hypertension, and provides insight into stroke targets to promote cell survival, angiogenesis, neurogenesis, and most importantly, functional recovery after stroke. Throughout the world, stroke is still a leading cause of mortality and morbidity; each year approximately 15 million people worldwide suffer from stroke. Stroke is now the leading cause of death and disability in China. Large communities of stroke survivors are eagerly awaiting scientific advances in transnational stroke research that would offer neuroprotective therapeutics for acute stroke management, or rehabilitation and regenerative strategies utilizing novel stem cell-based approaches. While research is ongoing, the Editors have compiled this volume to help the further understanding of the pathophysiology of strokeand to review and identify future potential biomarkers. The book is written for students, researchers and physicians in neurosciences, neurology and neuroradiology.

A critical and comprehensive look at current state-of-the-art scientific and translational research being conducted internationally, in academia and industry, to address new ways to provide effective treatment to victims of ischemic and hemorrhagic stroke and other ischemic diseases. Currently stroke can be successfully treated through the administration of a thrombolytic, but the therapeutic window is short and many patients are not able to receive treatment. Only about 30% of patients are'cured'by available treatments. In 5 sections, the proposed volume will explore historical and novel neuroprotection mechanisms and targets, new and combination therapies, as well as clinical trial design for some of the recent bench-side research.

This volume sets a basis for effective translational research. Authored by experts in the field of translational stroke research, each chapter specifically addresses one or more components of preclinical stroke research. The emphasis is placed on target identification and drug development using state-of-the-art in vitro and in vivo assays, in combination with in vitro toxicology assays, AMDE and clinical design.